Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

• Status: Recruiting
• Trial end date: 2029-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Collaborator: Eisai Inc.
• Treatments: Lenvatinib; Pembrolizumab

Criteria

Inclusion Criteria:

• Has a diagnosis of HCC confirmed by radiology, histology, or cytology

• Has HCC localized to the liver and not amenable to curative treatment

• Participants with Hepatitis C virus (HCV) are eligible if treatment was completed at least 1 month prior to starting study intervention

• Participants with Hepatitis B virus (HBV) are eligible

• Has adequately controlled blood pressure with or without antihypertensive medications

• Has adequate organ function

Exclusion Criteria:

• Is currently a candidate for liver transplantation

• Has had gastric bleeding within the last 6 months

• Has ascites that is not controlled with medication

• Has significant cardiovascular impairment within 12 months of the first dose of study intervention such as congestive heart failure

• Has a serious nonhealing wound, ulcer, or bone fracture

• Has received locoregional therapy to existing liver lesions